Idorsia Ltd

IDIA

Equity

ISIN CH0363463438 / Valor 36346343

SIX Swiss Exchange (2025-10-21)

CHF 3.74-1.80%

Idorsia Ltd
UMushroom community rating:

4.40 11 votes No rating yet

NegativeNeutralPositive

About company

Idorsia Ltd is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company aims to address significant unmet medical needs by advancing a diverse pipeline of drug candidates across various therapeutic areas. Idorsia's research and development efforts are concentrated on creating novel treatments that can improve patient outcomes. With a commitment to scientific excellence, the company leverages its expertise in drug discovery and development to bring new therapies to market. Headquartered in Switzerland, Idorsia operates with a global perspective, seeking to make a meaningful impact on healthcare through its innovative pharmaceutical solutions.

Summarized from source with an LLMView SourceSector: Healthcare

QUVIVIQ Sales Growth

Idorsia's QUVIVIQ™ sales reached CHF 58 million in H1 2025, marking a 145% increase compared to H1 2024, primarily fueled by strong performance in Europe and NDA approval with Simcere in China.

Net Revenue

The company reported net revenue of CHF 131 million for H1 2025, boosted by a CHF 32 million exclusivity fee and a CHF 40 million milestone payment from Simcere.

Operating Income and Loss

Idorsia achieved a US GAAP operating income of CHF 64 million in H1 2025, while the non-GAAP operating loss was CHF 15 million, reflecting effective financial management.

Cash Runway and Profitability

The company's cash runway has been extended to the end of 2026, keeping it on track to reach commercial profitability by 2026 and overall profitability by the end of 2027.

Strategic Partnerships and Pipeline Advancement

Idorsia is engaging in partnership discussions to enhance the commercial opportunity for Aprocitentan (TRYVIO/JERAYGO) and is advancing key assets in its pipeline, including initiatives aimed at expanding strategic partnerships.

Summarized from source with an LLMView Source

Key figures

226%1Y

-72.3%3Y

-83.5%5Y

Performance

115%1Y

98.4%3Y

79.9%5Y

Volatility

982 M

Market cap (USD)

1,096,141

Daily traded volume (Shares)

0.849 / 0.78

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.40

11 votes

Performance:

3.80

Innovation:

4.73

Society:

4.33

Nature:

4.13

Theo Clausen

Switzerland, 16 Oct 2025

In the last days an important capital increase has been done by Idorisa to have avaible cash to sell there medicaments. I see long term return in profitabilty for the company.